Recruiting Studies
Advanced SearchData: ClinicalTrials.gov · Source of record for eligibility and locations
Top Cities for Waldenstrom Macroglobulinemia Clinical Trials
Waldenstrom Macroglobulinemia clinical trials are recruiting across 29 cities. Here are the cities with the most active studies:
Waldenstrom Macroglobulinemia Trial Phases
7 research organizations are sponsoring waldenstrom macroglobulinemia trials.
About Waldenstrom Macroglobulinemia
Waldenstrom macroglobulinemia is a rare type of non-Hodgkin lymphoma where cancer cells produce large amounts of an abnormal protein called macroglobulin. It progresses slowly and may not require immediate treatment. Options include targeted therapy, chemotherapy, and plasmapheresis.
Clinical trials are advancing new treatments for waldenstrom macroglobulinemia. Currently, 7 studies are recruiting a combined 1,379 participants across the United States. Research is being conducted by 7 organizations including National Heart, Lung, and Blood Institute (NHLBI), BeiGene, National Cancer Institute (NCI) and 4 others.
2026 Waldenstrom Macroglobulinemia Research Landscape
As of July 2026, the waldenstrom macroglobulinemia clinical trial landscape includes 7 actively recruiting studies across 29 cities in the United States. These studies are collectively seeking 1,379 participants, with an average enrollment target of 197 per study.
The research spans multiple phases of development: 4 studies are in PHASE2.
Research is being led by 7 different organizations, including National Heart, Lung, and Blood Institute (NHLBI), BeiGene, National Cancer Institute (NCI), Brigham and Women's Hospital, Massachusetts General Hospital, and 2 others.
Geographically, waldenstrom macroglobulinemia trials are most concentrated in Boston, Massachusetts (4 trials); Bethesda, Maryland (1 trial); Huntsville, Alabama (1 trial); Mobile, Alabama (1 trial); Duarte, California (1 trial) and 7 other cities.
Featured Waldenstrom Macroglobulinemia Studies
Highlighted recruiting studies for waldenstrom macroglobulinemia, selected by enrollment size and research scope.
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Background The development of new technologies now allow scientists to investigate the molecular basis and clinical manifestations of monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). Applying these methods in a natural history st...
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
This is a hybrid (retrospective and prospective) non-interventional registry study to further describe the clinical profile of zanubrutinib in Waldenström macroglobulinemia (WM) participants with and without specific mutations and from racial and ethnic minority groups. Data collected from this registry study will be used to better understand the clinical benefit and safety of zanubrutinib for the...
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is fo...
Frequently Asked Questions About Waldenstrom Macroglobulinemia Clinical Trials
Are there waldenstrom macroglobulinemia clinical trials near me?
Yes, there are 7 waldenstrom macroglobulinemia clinical trials currently recruiting across 29+ cities in the United States, including Boston, Massachusetts; Bethesda, Maryland; Huntsville, Alabama. Browse the studies above to find one at a location convenient for you.
How do I join a waldenstrom macroglobulinemia clinical trial?
To join a waldenstrom macroglobulinemia clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are waldenstrom macroglobulinemia clinical trials free?
Yes, participation in waldenstrom macroglobulinemia clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of waldenstrom macroglobulinemia treatments are being studied?
Current waldenstrom macroglobulinemia clinical trials are testing a range of approaches across PHASE2 (4 studies). These include new drugs, combination therapies, medical devices, and other interventions sponsored by 7 research organizations.
Is it safe to participate in waldenstrom macroglobulinemia clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated July 16, 2026 from ClinicalTrials.gov
About This Data
Data: ClinicalTrials.gov · Source of record for eligibility and locations
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated July 16, 2026 · Data from ClinicalTrials.gov